Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-06
2007-02-06
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S332000, C546S255000, C546S256000, C546S257000
Reexamination Certificate
active
10377928
ABSTRACT:
The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
REFERENCES:
patent: 5354761 (1994-10-01), Stanek et al.
patent: 5474771 (1995-12-01), Lederman et al.
patent: 0 541 042 (1993-05-01), None
patent: WO 99/35109 (1999-07-01), None
patent: WO 00/22649 (2000-04-01), None
Pryor et al., “The Activated Core Approach to Combinatorial Chemistry: A Selection of New Core Molecules” Tetrahedron 54: 4107-4124 (1998).
Carter Mary-Beth
Hsu Yen-Ming
Jindal Satish
Kirkovsky Leonid
Lenz George R.
Biogen Inc.
Fish & Neave IP Group of Ropes & Gray LLP
Haley Jr. James F.
Morris Patricia L.
Pierri Margaret A.
LandOfFree
CD40:CD154 binding interrupter compounds and use thereof to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD40:CD154 binding interrupter compounds and use thereof to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD40:CD154 binding interrupter compounds and use thereof to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3825657